Search Results - takashi+tsukamoto

3 Results Sort By:
Novel Sigma-1 Receptor Ligand
Unmet NeedAlzheimer’s disease (AD) is a neurodegenerative disease that affects over 5 million people in North America. AD leads to nerve cell death and tissue loss in the brain, shrinking the brain and affecting many of its functions. The global AD population is steadily growing by 3-5% annually, with no cure or effective treatment (BCC Research). Current...
Published: 5/10/2024   |   Inventor(s): Takashi Tsukamoto, Run-Duo Gao, Robert Luedtke
Keywords(s):  
Category(s):  
DOPA and Caffeic Acid Analogs as Novel GCPII Inhibitors
Unmet NeedGlutamate is the primary excitatory neurotransmitter in the human brain [1]. Excessive glutamate signaling can disrupt calcium homeostasis, leading to mitochondrial dysfunction, the overproduction of reactive oxygen species, and neuron loss via necrotic or apoptotic pathways [2]. This phenomenon, known as excitotoxicity, contributes to disease...
Published: 5/10/2024   |   Inventor(s): Barbara Slusher, Rana Rais, Takashi Tsukamoto
Keywords(s):  
Category(s): Clinical and Disease Specializations > Neurology, Technology Classifications, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules
Glutaminase Inhibitor Discovery and Nanoparticle-Enhanced Delivery for Cancer Therapy
Glutaminase Inhibitor Discovery and Nanoparticle-Enhanced Delivery for cancer therapyJHU REF: C13142 Invention novelty: An improved glutaminase (GLS) inhibitors delivery system to enhance efficacy and prolong glutaminase inhibitor drug levels in tumor for improve treatment of pancreatic cancer. Value Proposition: Currently available glutaminase inhibitors...
Published: 5/9/2024   |   Inventor(s): Barbara Slusher, Jie Fu, Justin Hanes, Qingguo Xu, Quy Hoa Le Thi, Takashi Tsukamoto
Keywords(s): Adenocarcinoma, Antagonists/Inhibitors, Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Non-novel, Off-the-shelf, Pancreatic Cancer, Pancreatic ductal adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum